



Zeltia reports first quarter sales of € 31.1 million and Reduces operating costs by 2.5%

Madrid, Spain 26 April 2012: Spain's largest biotechnology company, Zeltia S.A. (Madrid: ZEL) ("Zeltia" or the "Company"), today announces its un-audited consolidated results for the quarter ending 31st March 2012. The report is compiled under International Financial Reporting Standards (IFRS). The full report is available at www.zeltia.com.

Net sales of the Zeltia Group ('Zeltia' or the 'Company') for the first quarter 2012 were €31.3 million (Q1 2011: €35 million). Of the total net sales, 57% were generated by the biopharmaceutical segment, totalling €17.8 million (Q1 2011: €20.7 million). Of these, €16.4 million are attributed to the sales of Yondelis (Q1 2011: €19.6 million). Notably, in March last year the Company recorded income from a delivery of active pharmaceutical ingredient to Janssen (Johnson & Johnson) of €2.4 million. Eliminating the effect of this item, commercial sales decreased by 4.2% year on year. This was largely due to the ongoing shortage of Caelyx, which is used in combination with Yondelis for the treatment of ovarian cancer.

The net sales of the consumer chemicals segment were €13.3 million (Q1 2011: €14.5 million). Whilst varnishes and protective wood coatings saw an increase in sales, other business lines were impacted by the ongoing consumer slow down in European economies and particularly in the domestic market.



Focus on operational efficiency across the Group resulted in a reduction of operating costs by 2.5% during the first quarter.

The previously announced focusing of the budget at Noscira on the ongoing Phase II trial in Alzheimer's disease resulted in a decrease of 3.6% in R&D investment during the period.

About Zeltia S.A.

Zeltia S.A. is the largest biotechnology company in Spain and the world leader in marine derived anti-cancer drugs. The Group's principal activities are to manufacture bio-pharmaceutical products especially the development of marine derived anti-cancer drugs and CNS pathologies treatments. Other activities include developing diagnostics kits; RNAi technology-based therapeutical applications and the manufacture and sale of consumer chemicals.

For more information +34 91 444 4500

This note is also available on the Zeltia's website: www.zeltia.com